Ting-Chao Chou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3995055/publications.pdf

Version: 2024-02-01

252 papers

28,528 citations

20759 60 h-index

164

5364

273 all docs

273 docs citations

times ranked

273

30816 citing authors

g-index

#	Article	IF	CITATIONS
1	Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 1984, 22, 27-55.	2.9	6,213
2	Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Research, 2010, 70, 440-446.	0.4	4,304
3	Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacological Reviews, 2006, 58, 621-681.	7.1	4,172
4	Human neutralizing monoclonal antibodies of the lgG1 subtype protect against mucosal simian–human immunodeficiency virus infection. Nature Medicine, 2000, 6, 200-206.	15.2	841
5	Analysis of combined drug effects: a new look at a very old problem. Trends in Pharmacological Sciences, 1983, 4, 450-454.	4.0	508
6	Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol Design. Journal of the National Cancer Institute, 1994, 86, 1517-1524.	3.0	475
7	Generalized Equations for the Analysis of Inhibitions of Michaelis-Menten and Higher-Order Kinetic Systems with Two or More Mutually Exclusive and Nonexclusive Inhibitors. FEBS Journal, 1981, 115, 207-216.	0.2	365
8	Irinotecan is an active agent in untreated patients with metastatic colorectal cancer Journal of Clinical Oncology, 1996, 14, 709-715.	0.8	304
9	Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. Journal of Theoretical Biology, 1976, 59, 253-276.	0.8	288
10	Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science, 1987, 235, 1376-1379.	6.0	287
11	Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrobial Agents and Chemotherapy, 1987, 31, 168-172.	1.4	240
12	Preclinical <i>>versus </i> clinical drug combination studies. Leukemia and Lymphoma, 2008, 49, 2059-2080.	0.6	233
13	The Total Synthesis of Dynemicin A Leading to Development of a Fully Contained Bioreductively Activated Enediyne Prodrug. Journal of the American Chemical Society, 1996, 118, 9509-9525.	6.6	212
14	Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9642-9647.	3.3	209
15	Pharmacokinetic Interactions Augment Toxicities of Sirolimus/Cyclosporine Combinations. Journal of the American Society of Nephrology: JASN, 2001, 12, 1059-1071.	3.0	200
16	Quantitation of chemopreventive synergism between (-)-epigallocatechin- 3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. Carcinogenesis, 1998, 19, 419-424.	1.3	195
17	SYNERGISTIC INTERACTIONS OF CYCLOSPORINE AND RAPAMYCIN TO INHIBIT IMMUNE PERFORMANCES OF NORMAL HUMAN PERIPHERAL BLOOD LYMPHOCYTES IN VITRO. Transplantation, 1991, 51, 232-238.	0.5	188
18	p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes and Development, 2002, 16, 984-993.	2.7	181

#	Article	IF	CITATIONS
19	Remote Effects in Macrolide Formation through Ring-Forming Olefin Metathesis:Â An Application to the Synthesis of Fully Active Epothilone Congeners. Journal of the American Chemical Society, 1997, 119, 2733-2734.	6.6	180
20	BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrobial Agents and Chemotherapy, 1991, 35, 305-308.	1.4	176
21	Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 15798-15802.	3.3	163
22	Selective, covalent modification of Â-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 5686-5691.	3.3	158
23	Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus Challenge. Journal of Virology, 2001, 75, 7470-7480.	1.5	158
24	Total Synthesis of($\hat{a}\in$ ")-Epothilone B: An Extension of the Suzuki Coupling Method and Insights into Structure $\hat{a}\in$ "Activity Relationships of the Epothilones. Angewandte Chemie International Edition in English, 1997, 36, 757-759.	4.4	156
25	Two-Drug Combinations of Zidovudine, Didanosine, and Recombinant Interferon-Â A Inhibit Replication of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Synergistically In Vitro. Journal of Infectious Diseases, 1991, 164, 646-655.	1.9	141
26	Synergistic Anticancer Effects of Ganciclovir/Thymidine Kinase and 5-Fluorocytosine/Cytosine Deaminase Gene Therapies. Journal of the National Cancer Institute, 1998, 90, 370-380.	3.0	139
27	Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. Antimicrobial Agents and Chemotherapy, 1992, 36, 808-818.	1.4	138
28	Staurosporine and ent-Staurosporine:  The First Total Syntheses, Prospects for a Regioselective Approach, and Activity Profiles1. Journal of the American Chemical Society, 1996, 118, 2825-2842.	6.6	135
29	Synergistic Neutralization of HIV-1 by Human Monoclonal Antibodies Against the V3 Loop and the CD4-Binding Site of gp120. AIDS Research and Human Retroviruses, 1992, 8, 461-467.	0.5	122
30	Structure–Activity Relationship of the Epothilones and the First In Vivo Comparison with Paclitaxel. Angewandte Chemie International Edition in English, 1997, 36, 2093-2096.	4.4	121
31	On the Remarkable Antitumor Properties of Fludelone: How We Got There. Angewandte Chemie - International Edition, 2005, 44, 2838-2850.	7.2	116
32	The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 8113-8118.	3.3	114
33	Highly Concise Routes to Epothilones:Â The Total Synthesis and Evaluation of Epothilone 490. Journal of the American Chemical Society, 2002, 124, 9825-9832.	6.6	113
34	Lamivudine or Stavudine in Two- and Three-Drug Combinations against Human Immunodeficiency Virus Type 1 Replication In Vitro. Journal of Infectious Diseases, 1996, 173, 355-364.	1.9	103
35	Anti-Human Immunodeficiency Virus Interactions of SCH-C (SCH 351125), a CCR5 Antagonist, with Other Antiretroviral Agents In Vitro. Antimicrobial Agents and Chemotherapy, 2002, 46, 1336-1339.	1.4	93
36	Discovery of (E)-9,10-Dehydroepothilones through Chemical Synthesis:Â On the Emergence of 26-Trifluoro-(E)-9,10-dehydro-12,13-desoxyepothilone B as a Promising Anticancer Drug Candidate. Journal of the American Chemical Society, 2004, 126, 10913-10922.	6.6	93

#	Article	IF	CITATIONS
37	Complex Target-Oriented Total Synthesis in the Drug Discovery Process:Â The Discovery of a Highly Promising Family of Second Generation Epothilones. Journal of the American Chemical Society, 2003, 125, 2899-2901.	6.6	90
38	Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection. Clinical and Experimental Immunology, 1997, 108, 63-68.	1.1	89
39	Ch'ang Shan, a Chinese Antimalarial Herb. Science, 1946, 103, 59-59.	6.0	82
40	9-Substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships. Journal of Medicinal Chemistry, 1995, 38, 3226-3235.	2.9	82
41	Strong in Vitro Synergy Between the Fusion Inhibitor T-20 and the CXCR4 Blocker AMD-3100. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 99-102.	0.9	82
42	Three-Drug Synergistic Inhibition of HIV-l Replication In Vitro by Zidovudine, Recombinant Soluble CD4, and Recombinant Interferon-alpha A. Journal of Infectious Diseases, 1990, 161, 1059-1067.	1.9	80
43	Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates. Bioorganic and Medicinal Chemistry, 2011, 19, 1987-1998.	1.4	79
44	Intercalating agents with covalent bond forming capability. A novel type of potential anticancer agents. 2. Derivatives of chrysophanol and emodin. Journal of Medicinal Chemistry, 1989, 32, 1594-1599.	2.9	78
45	EFFECTS OF THE PHARMACOKINETIC INTERACTION BETWEEN ORALLY ADMINISTERED SIROLIMUS AND CYCLOSPORINE ON THE SYNERGISTIC PROLONGATION OF HEART ALLOGRAFT SURVIVAL IN RATS1. Transplantation, 1996, 62, 986-994.	0.5	77
46	Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication in vitro by castanospermine and 3'-azido-3'-deoxythymidine. Antimicrobial Agents and Chemotherapy, 1989, 33, 53-57.	1.4	76
47	Human Immunodeficiency Virus Type 1 (HIV-1) Inhibitory Interactions between Protease Inhibitor Ro 31-8959 and Zidovudine, 2',3'-Dideoxycytidine, or Recombinant Interferon-ÂA against Zidovudine-Sensitive or -Resistant HIV-1 In Vitro. Journal of Infectious Diseases, 1992, 166, 1143-1146.	1.9	76
48	Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrobial Agents and Chemotherapy, 1992, 36, 1559-1562.	1.4	73
49	Co-exposure to low doses of the food contaminants deoxynivalenol and nivalenol has a synergistic inflammatory effect on intestinal explants. Archives of Toxicology, 2017, 91, 2677-2687.	1.9	71
50	Synergistic Neutralization of Simian-Human Immunodeficiency Virus SHIV-vpu ⁺ by Triple and Quadruple Combinations of Human Monoclonal Antibodies and High-Titer Anti-Human Immunodeficiency Virus Type 1 Immunoglobulins. Journal of Virology, 1998, 72, 3235-3240.	1.5	69
51	A Novel Aldol Condensation with 2-Methyl-4-pentenal and Its Application to an Improved Total Synthesis of Epothilone B. Angewandte Chemie - International Edition, 1998, 37, 2675-2678.	7.2	68
52	Insights into Long-Range Structural Effects on the Stereochemistry of Aldol Condensations:Â A Practical Total Synthesis of Desoxyepothilone F. Journal of the American Chemical Society, 2001, 123, 5249-5259.	6.6	68
53	Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. Antimicrobial Agents and Chemotherapy, 1986, 30, 189-191.	1.4	66
54	Strong in Vitro Synergy Between the Fusion Inhibitor T-20 and the CXCR4 Blocker AMD-3100. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 25, 99-102.	0.9	64

#	Article	IF	CITATIONS
55	Design of antineoplastic agents based on the '2-phenylnaphthalene-type' structural patternâ€"synthesis and biological activity studies of 11H-indolo[3.2-c]quinoline derivatives. European Journal of Medicinal Chemistry, 2003, 38, 101-107.	2.6	64
56	Synergistic Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Replication In Vitro by Recombinant Soluble CD4 and 3'-Azido-3'-Deoxythymidine. Journal of Infectious Diseases, 1989, 159, 837-844.	1.9	62
57	7-Silylcamptothecins (silatecans): A new family of camptothecin antitumor agents. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 3189-3194.	1.0	62
58	Reversal of anticancer multidrug resistance by the ardeemins. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 8369-8374.	3.3	62
59	Design and Total Synthesis of a Superior Family of Epothilone Analogues, which Eliminate Xenograft Tumors to a Nonrelapsable State. Angewandte Chemie - International Edition, 2003, 42, 4762-4767.	7.2	62
60	Upâ€regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a γ 1 34.5 deleted oncolytic herpes virus (G207). FASEB Journal, 2004, 18, 1001-1003.	0.2	62
61	Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13157-13162.	3.3	62
62	Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogs of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC). Journal of Medicinal Chemistry, 1990, 33, 2145-2150.	2.9	59
63	Synergistic Neutralization of a Chimeric SIV/HIV Type 1 Virus with Combinations of Human Anti-HIV Type 1 Envelope Monoclonal Antibodies or Hyperimmune Globulins. AIDS Research and Human Retroviruses, 1997, 13, 647-656.	0.5	59
64	Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. American Journal of Cancer Research, 2016, 6, 97-104.	1.4	58
65	Mechanism of S-adenosyl-L-methionine synthesis by purified preparations of bakers' yeast. Biochemistry, 1972, 11, 1065-1073.	1.2	57
66	Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. Cancer Biology and Therapy, 2006, 5, 48-53.	1.5	57
67	Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer. Clinical Cancer Research, 2008, 14, 1519-1528.	3.2	57
68	Novel Antitumor Indolizino [6,7- <i>b</i>) indoles with Multiple Modes of Action: DNA Cross-Linking and Topoisomerase I and II Inhibition. Journal of Medicinal Chemistry, 2013, 56, 1544-1563.	2.9	57
69	Effect of whole and fractionated cobra venom on sympathetic ganglionic transmission. European Journal of Pharmacology, 1969, 8, 326-330.	1.7	56
70	Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemotherapy and Pharmacology, 1993, 31, 259-264.	1.1	56
71	Total Synthesis as a Resource in Drug Discovery:Â The First In Vivo Evaluation of Panaxytriol and Its Derivatives. Journal of Organic Chemistry, 2005, 70, 10375-10380.	1.7	56
72	Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage. Bioorganic and Medicinal Chemistry, 2008, 16, 5413-5423.	1.4	56

#	Article	lF	Citations
73	On the Interactivity of Complex Synthesis and Tumor Pharmacology in the Drug Discovery Process:Â Total Synthesis and Comparative in Vivo Evaluations of the 15-Aza Epothilones. Journal of Organic Chemistry, 2001, 66, 4369-4378.	1.7	55
74	Fluorinated sugar analogs of potential anti-HIV-1 nucleosides. Journal of Medicinal Chemistry, 1991, 34, 1640-1646.	2.9	54
75	Design of antineoplastic agents on the basis of the 2-phenylnaphthalene-type structural pattern. 2. Synthesis and biological activity studies of benzo[b]naphtho[2,3-d]furan-6,11-dione derivatives. Journal of Medicinal Chemistry, 1993, 36, 4108-4112.	2.9	54
76	Totalsynthese von (―)â€Epothilon B: eine Erweiterung der Suzukiâ€Kupplung und Erkenntnisse Ã⅓ber Strukturâ€Wirkungsâ€Beziehungen der Epothilone. Angewandte Chemie, 1997, 109, 775-777.	1.6	54
77	Stereoselective syntheses and evaluation of compounds in the 8-desmethylepothilone A series: Some surprising observations regarding their chemical and biological properties. Tetrahedron Letters, 1997, 38, 4529-4532.	0.7	52
78	5-Fluorouracil and Gemcitabine Potentiate the Efficacy of Oncolytic Herpes Viral Gene Therapy in the Treatment of Pancreatic Cancer. Journal of Gastrointestinal Surgery, 2005, 9, 1068-1079.	0.9	52
79	Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes. Bioorganic and Medicinal Chemistry, 2009, 17, 5614-5626.	1.4	52
80	Total Syntheses of [17]- and [18]Dehydrodesoxyepothilones B via a Concise Ring-Closing Metathesis-Based Strategy:Â Correlation of Ring Size with Biological Activity in the Epothilone Series. Journal of Organic Chemistry, 2002, 67, 7737-7740.	1.7	50
81	Radiation Therapy Potentiates Effective Oncolytic Viral Therapy in the Treatment of Lung Cancer. Annals of Thoracic Surgery, 2005, 80, 409-417.	0.7	50
82	Synthesis of Pluraflavin A "Aglycone― Journal of the American Chemical Society, 2008, 130, 16786-16790.	6.6	50
83	In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors. Antimicrobial Agents and Chemotherapy, 1990, 34, 82-88.	1.4	49
84	Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: A rationale for combination therapy with chemotherapeutic agents. International Journal of Cancer, 1995, 61, 409-415.	2.3	49
85	Synergistic Interaction of 2',3'-Dideoxycytidine and Recombinant Interferon-Â-A on Replication of Human Immunodeficiency Virus Type 1. Journal of Infectious Diseases, 1988, 158, 378-385.	1.9	48
86	Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine. Antimicrobial Agents and Chemotherapy, 1991, 35, 2003-2011.	1.4	48
87	Total Synthesis and Antitumor Activity of 12,13-Desoxyepothilone F:Â An Unexpected Solvolysis Problem at C15, Mediated by Remote Substitution at C21. Journal of Organic Chemistry, 2000, 65, 6525-6533.	1.7	48
88	Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. Cancer Gene Therapy, 2001, 8, 662-668.	2,2	48
89	90-kDa Heat Shock Protein Inhibition Abrogates the Topoisomerase I Poison-Induced G ₂ /M Checkpoint in p53-Null Tumor Cells by Depleting Chk1 and Wee1. Molecular Pharmacology, 2009, 75, 124-133.	1.0	48
90	A rapid assay procedure for ATP:l-methionine adenosyltransferase. Biochimica Et Biophysica Acta - Biomembranes, 1972, 276, 399-406.	1.4	47

#	Article	IF	CITATIONS
91	Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis. Antimicrobial Agents and Chemotherapy, 1986, 30, 491-498.	1.4	47
92	Regulatory properties of adenosine triphosphate- <scp>l</scp> -methionine <i>S</i> -adenosyltransferase of rat liver. Biochemical Journal, 1973, 135, 43-57.	1.7	46
93	On the Introduction of a Trifluoromethyl Substituent in the Epothilone Setting:  Chemical Issues Related to Ring Forming Olefin Metathesis and Earliest Biological Findings. Organic Letters, 2002, 4, 4081-4084.	2.4	46
94	Synthesis and Conformational Analysis of (E)-9,10-Dehydroepothilone B: A Suggestive Link between the Chemistry and Biology of Epothilones. Angewandte Chemie - International Edition, 2003, 42, 2518-2521.	7.2	46
95	Potent DNA-directed alkylating agents: Synthesis and biological activity of phenyl N-mustard–quinoline conjugates having a urea or hydrazinecarboxamide linker. Bioorganic and Medicinal Chemistry, 2010, 18, 2285-2299.	1.4	46
96	Drug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice. Synergy, 2016, 3, 15-30.	1.1	45
97	Design of Antineoplastic Agents Based on the "2-Phenylnaphthalene-Type―Structural Pattern. 4. Synthesis and Biological Activity of 2-Chloro-3-(substituted phenoxy)-1,4-naphthoquinones and Related 5,8-Dihydroxy-1,4-naphthoquinones. Journal of Medicinal Chemistry, 1999, 42, 405-408.	2.9	44
98	Potent Antitumor 9-Anilinoacridines and Acridines Bearing an AlkylatingN-Mustard Residue on the Acridine Chromophore:Â Synthesis and Biological Activity. Journal of Medicinal Chemistry, 2006, 49, 3710-3718.	2.9	44
99	Radiation-Induced Cellular DNA Damage Repair Response Enhances Viral Gene Therapy Efficacy in the Treatment of Malignant Pleural Mesothelioma. Annals of Surgical Oncology, 2006, 14, 258-269.	0.7	44
100	Synthesis of the acridone alkaloids, glyfoline and congeners. Structure-activity relationship studies of cytotoxic acridones. Journal of Medicinal Chemistry, 1992, 35, 2703-2710.	2.9	43
101	Drug combinations: From laboratory to practice. Translational Research, 1998, 132, 6-8.	2.4	43
102	THE SYNERGISTIC INTERACTIONS IN VITRO AND IN VIVO OF BREQUINAR SODIUM WITH CYCLOSPORINE OR RAPAMYCIN ALONE AND IN TRIPLE COMBINATION. Transplantation, 1993, 55, 894-900.	0.5	42
103	Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrobial Agents and Chemotherapy, 1996, 40, 1346-1351.	1.4	42
104	Potent Crossâ€Group Neutralization of Primary Human Immunodeficiency Virus Isolates with Monoclonal Antibodiesâ€"Implications for Acquired Immunodeficiency Syndrome Vaccine. Journal of Infectious Diseases, 2004, 189, 71-74.	1.9	42
105	The mass-action law based algorithms for quantitative econo-green bio-research. Integrative Biology (United Kingdom), 2011, 3, 548-559.	0.6	42
106	Design of antineoplastic agents on the basis of the "2â€phenylâ€naphthaleneâ€type―structural pattern. 3. synthesis and biological activity evaluation of 5 <i>H</i> à€benzo[<i>b</i>]naphthoâ€{2,3â€ <i>d</i>]pyrroleâ€6,11â€dione derivatives. Journal of Heterocyclic Chemistry, 1996, 33, 113-117.	1.4	41
107	Therapeutic Cure against Human Tumor Xenografts in Nude Mice by a Microtubule Stabilization Agent, Fludelone, via Parenteral or Oral Route. Cancer Research, 2005, 65, 9445-9454.	0.4	41
108	Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors. Journal of Neuro-Oncology, 2011, 101, 379-390.	1.4	41

#	Article	IF	Citations
109	Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Research, 2002, 62, 6909-15.	0.4	41
110	ANALYSIS OF THE INTERACTIONS OF IMMUNOSUPPRESSIVE DRUGS WITH CYCLOSPORINE IN INHIBITING DNA PROLIFERATION. Transplantation, 1990, 49, 463-471.	0.5	40
111	Medical Management of Benign Prostatic Hyperplasia: A Canine Model Comparing the in Vivo Efficacy of Alpha-1 Adrenergic Antagonists in the Prostate. Journal of Urology, 1993, 149, 395-399.	0.2	39
112	Incorporation of metabolites of 2'-fluoro-5-iodo- $1-\hat{l}^2$ -d-arabinofuranosylcytosine into deoxyribonucleic acid of neoplastic and normal mammalian tissues. Biochemical Pharmacology, 1982, 31, 1103-1108.	2.0	38
113	Synthesis and biological effects of 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil. Antimicrobial Agents and Chemotherapy, 1987, 31, 1355-1358.	1.4	38
114	The Synergistic Effects Of Cyclosporine, Sirolimus, And Brequinar On Heart Allograft Survival In Mice. Transplantation, 1995, 59, 177-182.	0.5	38
115	Frequently asked questions in drug combinations and the mass-action law-based answers. Synergy, 2014, 1, 3-21.	1.1	38
116	Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for Thyroid Cancer Therapy. PLoS ONE, 2012, 7, e46726.	1.1	38
117	Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. Cancer Gene Therapy, 2014, 21, 283-289.	2.2	37
118	Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells. Cancer Chemotherapy and Pharmacology, 1985, 14, 206-10.	1.1	36
119	Synthesis and antitumor evaluation of novel Benzo[d]pyrrolo[2,1-b]thiazole derivatives. European Journal of Medicinal Chemistry, 2012, 53, 28-40.	2.6	36
120	A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. PLoS ONE, 2017, 12, e0172315.	1.1	36
121	Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment. PLoS ONE, 2013, 8, e77684.	1.1	35
122	On the determination of availability of ligand binding sites in steady-state systems. Journal of Theoretical Biology, 1977, 65, 345-356.	0.8	34
123	Nucleosides. CXXXV. Synthesis of some 9-(2-deoxy-2-fluoroBETAD-arabinofuranosyl)-9H-purines and their biological activities Chemical and Pharmaceutical Bulletin, 1989, 37, 336-339.	0.6	34
124	Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice. Cancer Chemotherapy and Pharmacology, 2005, 56, 379-390.	1.1	34
125	Inhibition of cell growth and macromolecule biosynthesis of human promyelocytic leukemic cells by acridone alkaloids. Phytotherapy Research, 1989, 3, 237-242.	2.8	33
126	Passive immunization against oral AIDS virus transmission: An approach to prevent mother-to-infant HIV-1 transmission?. Journal of Medical Primatology, 2001, 30, 190-196.	0.3	33

#	Article	IF	CITATIONS
127	Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity. Bioorganic and Medicinal Chemistry, 2005, 13, 3993-4006.	1.4	33
128	TAK-220, a Novel Small-Molecule CCR5 Antagonist, Has Favorable Anti-Human Immunodeficiency Virus Interactions with Other Antiretrovirals In Vitro. Antimicrobial Agents and Chemotherapy, 2005, 49, 3483-3485.	1.4	33
129	Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. Oncotarget, 2017, 8, 41294-41304.	0.8	33
130	THE IMMUNOSUPPRESSIVE ANTAGONISM OF LOW DOSES OF FK506 AND CYCLOSPORINE. Transplantation, 1991, 52, 121-127.	0.5	32
131	Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrobial Agents and Chemotherapy, 1994, 38, 656-661.	1.4	32
132	Antitumor AHMA Linked to DNA Minor Groove Binding Agents:Â Synthesis and Biological Evaluation. Journal of Medicinal Chemistry, 2002, 45, 4485-4493.	2.9	32
133	Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. British Journal of Surgery, 2010, 97, 1385-1394.	0.1	32
134	$5\hat{a}$ €²-Hydrogenphosphonates and $5\hat{a}$ €²-Methylphosphonates of Sugar Modified Pyrimidine Nucleosides as Potential Anti-HIV-1 Agents. ^{1 < /sup>. Nucleosides & Nucleotides, 1992, 11, 177-196.}	0.5	31
135	Assessment of Synergistic and Antagonistic Effects of Chemotherapeutic Agents in vitro. Contributions To Gynecology and Obstetrics, 1994, 19, 91-107.	0.1	31
136	Antagonism between Human Immunodeficiency Virus Type 1 Protease Inhibitors Indinavir and Saquinavir In Vitro. Journal of Infectious Diseases, 1997, 176, 265-268.	1.9	31
137	Synthesis and antitumor activity of 5-(9-acridinylamino)anisidine derivatives. Bioorganic and Medicinal Chemistry, 2005, 13, 6513-6520.	1.4	30
138	HERPES SIMPLEX VIRUS BASED GENE THERAPY ENHANCES THE EFFICACY OF MITOMYCIN C FOR THE TREATMENT OF HUMAN BLADDER TRANSITIONAL CELL CARCINOMA. Journal of Urology, 2005, 174, 741-746.	0.2	30
139	Design of Antineoplastic Agents on the Basis of the "2-Phenylnaphthalene-Type" Structural Pattern. I. Synthesis of Substituted 3-Phenylquinazolones, Benzoxazolo[2,3-b]quinazolones and Benzothiazolo[2,3-b]quinazolones. Heterocycles, 1993, 35, 775.	0.4	28
140	Enediyne Quinone Imines: Truncated, Biologically Active Dynemicin Congeners. Angewandte Chemie International Edition in English, 1995, 33, 2477-2479.	4.4	28
141	Synthesis and Structureâ 'Activity Relationships of Potential Anticancer Agents: Alkylcarbamates of 3-(9-Acridinylamino)-5-hydroxymethylaniline. Journal of Medicinal Chemistry, 1999, 42, 4741-4748.	2.9	28
142	Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. Gynecologic Oncology, 1990, 38, 315-322.	0.6	27
143	Drug Combinations and Effect Parameters of Zidovudine, Stavudine, and Nevirapine in Standardized Drug-Sensitive and Resistant HIV Type 1 Strains*. AIDS Research and Human Retroviruses, 1996, 12, 507-517.	0.5	27
144	Novel DNA-directed alkylating agents: Design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker. Bioorganic and Medicinal Chemistry, 2009, 17, 1264-1275.	1.4	27

#	Article	IF	Citations
145	Differential Effect of Imatinib and Synergism of Combination Treatment with Chemotherapeutic Agents in Malignant Glioma Cells. Basic and Clinical Pharmacology and Toxicology, 2009, 104, 241-252.	1.2	27
146	Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemotherapy and Pharmacology, 1995, 37, 222-228.	1.1	26
147	Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells. Cancer Chemotherapy and Pharmacology, 2003, 52, 41-46.	1.1	26
148	Design, synthesis, and biological evaluation of novel water-soluble N-mustards as potential anticancer agents. Bioorganic and Medicinal Chemistry, 2011, 19, 471-485.	1.4	26
149	Synergistic Inhibition of Epstein-Barr Virus: Transformation of B Lymphocytes by and Interferon and by 3'-Azido-3'-Deoxythymidine. Journal of Infectious Diseases, 1989, 159, 248-254.	1.9	25
150	On the Total Synthesis and Preliminary Biological Evaluations of 15(R) and 15(S) Aza-dEpoB:  A Mitsunobu Inversion at C15 in Pre-Epothilone Fragments. Organic Letters, 2000, 2, 1637-1639.	2.4	25
151	Probing the SAR of dEpoB via Chemical Synthesis:Â A Total Synthesis Evaluation of C26-(1,3-dioxolanyl)-12,13-desoxyepothilone B. Journal of Organic Chemistry, 2002, 67, 7730-7736.	1.7	25
152	Primary African HIV Clade A and D Isolates: Effective Cross-Clade Neutralization with a Quadruple Combination of Human Monoclonal Antibodies Raised against Clade B. AIDS Research and Human Retroviruses, 2003, 19, 125-131.	0.5	25
153	Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Cancer Chemotherapy and Pharmacology, 2006, 58, 640-653.	1.1	25
154	Synthesis of cyclopentanthraquinones: analogs of mitomycin C. Journal of Organic Chemistry, 1993, 58, 1680-1686.	1.7	24
155	Comparison of dose-effect relationships of carcinogens following low-dose chronic exposure and high-dose single injection: an analysis by the median-effect principle. Carcinogenesis, 1980, 1, 203-213.	1.3	23
156	New analogues of AHMA as potential antitumor agents: synthesis and biological activity. Bioorganic and Medicinal Chemistry, 2003, 11 , 4959-4969.	1.4	23
157	The binding of colchicine by sarcoma 180 cells. Biochemical Pharmacology, 1968, 17, 477-481.	2.0	22
158	Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4719-4722.	1.0	22
159	Synthesis and in vitro cytotoxicity of 9-anilinoacridines bearing N-mustard residue on both anilino and acridine rings. European Journal of Medicinal Chemistry, 2009, 44, 3056-3059.	2.6	22
160	Second generation epothilones: Discovery of fludelone and its extraordinary antitumor properties. Drugs of the Future, 2005, 30, 737.	0.0	22
161	Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-Cell Viability Assay. Breast Cancer Research and Treatment, 1993, 28, 21-27.	1.1	21
162	Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. Journal of Antimicrobial Chemotherapy, 2004, 53, 464-468.	1.3	21

#	Article	IF	CITATIONS
163	Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)norspermine. Cancer Letters, 2007, 250, 311-322.	3.2	21
164	Kinetic properties and inhibition of Acinetobacter glutaminase-asparaginase. Biochemical Pharmacology, 1983, 32, 971-977.	2.0	20
165	Effect of 9-(1,3-Dihydroxy-2-Propoxymethyl)Guanine and Recombinant Human Interferon Alone and in Combination on Simian Varicella Virus Infection in Monkeys. Journal of Infectious Diseases, 1987, 156, 607-614.	1.9	20
166	Effects of Anthraquinones of Polygonum cuspidatumon HL-60 Cells. Planta Medica, 1988, 54, 413-414.	0.7	20
167	A structure-activity relationship study of batracylin analogues. Pharmaceutical Research, 1993, 10, 918-923.	1.7	20
168	Novel bifunctional alkylating agents, 5,10-dihydropyrrolo[1,2-b]isoquinoline derivatives, synthesis and biological activity. Bioorganic and Medicinal Chemistry, 2011, 19, 275-286.	1.4	20
169	BENEFICIAL EFFECT OF GRAFT PERFUSION WITH ANTI-T CELL RECEPTOR MONOCLONAL ANTIBOCIES ON SURVIVAL OF SMALL BOWEL ALLOGRAFTS IN RAT RECIPIENTS TREATED WITH BREQUINAR ALONE OR IN COMBINATION WITH CYCLOSPORINE AND SIROLIMUS1. Transplantation, 1996, 61, 458-464.	0.5	20
170	The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. American Journal of Cancer Research, 2011, 1, 925-54.	1.4	20
171	Chemical synthesis and biological activities of 5-deazaaminopterin analogs bearing substituent(s) at the 5- and/or 7-position(s). Journal of Medicinal Chemistry, 1988, 31, 1209-1215.	2.9	19
172	Oncolytic vaccinia virus in combination with radiation shows synergistic antitumor efficacy in pancreatic cancer. Cancer Letters, 2014, 344, 282-290.	3.2	19
173	Incorporation and metabolism of $2\hat{a}\in^2$ -fluoro-5-substituted arabinosyl pyrimidines and their selective inhibition of viral DNA synthesis in herpes simplex virus type 1 (HSV-1)-infected and mock-infected Vero cells. Antiviral Research, 1988, 10, 153-166.	1.9	18
174	15 AU81, A PROSTACYCLIN ANALOG, POTENTIATES IMMUNOSUPPRESSION AND MITIGATES RENAL INJURY DUE TO CYCLOSPORINE. Transplantation, 1993, 55, 1124-1127.	0.5	18
175	Production of l-asparagine by tumor cells and the effect of asparagine analogs. Biochemical Pharmacology, 1972, 21, 39-48.	2.0	17
176	Kinetics and substrate specificity of human and canine cytidine deaminase. Biochemical Pharmacology, 1986, 35, 1199-1201.	2.0	17
177	IMMUNOSUPPRESSIVE EFFECTS OF DEFIBROTIDE. Transplantation, 1993, 56, 928-933.	0.5	17
178	The synthesis and evaluation of 12,13-benzodesoxyepothilone B: a highly convergent route. Tetrahedron Letters, 1999, 40, 6895-6898.	0.7	17
179	Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluorobetaD-arabinofuranosyluracil. Journal of Medicinal Chemistry, 1988, 31, 1642-1647.	2.9	16
180	Inhibition of Simian varicella virus infection of monkeys by $1-(2-{\rm deoxy-}2-{\rm fluoro-}1-{\rm i}^2-{\rm d-arabinofuranosyl})-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-{\rm i}^2. Antiviral Research, 1990, 13, 165-174.$	1.9	16

#	Article	IF	CITATIONS
181	Activity of roniciclib in medullary thyroid cancer. Oncotarget, 2018, 9, 28030-28041.	0.8	16
182	Synergy Determination Issues. Journal of Virology, 2002, 76, 10577-10578.	1.5	15
183	SYNERGISTIC IMMUNOSUPPRESSIVE ACTIONS OF CYCLOSPORINE WITH A MOUSE ANTI-RAT $\hat{l}\pm/\hat{l}^2$ -T CELL RECEPTOR MONOCLONAL ANTIBODY. Transplantation, 1994, 57, 1544-1547.	0.5	15
184	Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis. Cancer Chemotherapy and Pharmacology, 1993, 33, 245-250.	1,1	14
185	Synergistic interaction between castanospermine and tacrolimus in a rat heart allograft model. Transplantation Proceedings, 1997, 29, 1259-1260.	0.3	14
186	Multifaceted cytoprotection by synthetic polyacetylenes inspired by the ginseng-derived natural product, panaxytriol. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14336-14341.	3.3	14
187	TAK-652, a Novel CCR5 Inhibitor, has Favourable Drug Interactions with other Antiretrovirals <i>in Vitro</i> . Antiviral Therapy, 2005, 10, 967-968.	0.6	13
188	An in Vivo Evaluation of Alpha Adrenergic Receptors in Canine Prostate. Journal of Urology, 1989, 141, 1230-1233.	0.2	12
189	Title is missing!. Angewandte Chemie, 2003, 115, 2622-2625.	1.6	12
190	Combinatorial analysis of multiple substrateâ€"multiple product enzyme reactions. Journal of Theoretical Biology, 1972, 35, 285-297.	0.8	11
191	Three-Drug Synergistic Inhibition of HIV-1 Replication In Vitro by 3′-Fluoro-3′-Deoxythymidine, Recombinant Soluble CD4, and Recombinant Interferon-Alpha. AIDS Research and Human Retroviruses, 1992, 8, 589-595.	0.5	11
192	Cyclopent[a]anthraquinones as DNA-Intercalating Agents with Covalent Bond Formation Potential:Â Synthesis and Biological Activity. Journal of Medicinal Chemistry, 1996, 39, 2812-2818.	2.9	11
193	Interactions Among Combinations of Two and Three Protease Inhibitors Against Drug-Susceptible and Drug-Resistant HIV-1 Isolates. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 430.	0.9	11
194	Interactions Among Combinations of Two and Three Protease Inhibitors Against Drug-Susceptible and Drug-Resistant HIV-1 Isolates. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 430.	0.9	11
195	Novel 2â€Substituted Quinolinâ€4â€ylâ€benzenesulfonate Derivatives: Synthesis, Antiproliferative Activity, and Inhibition of Cellular Tubulin Polymerization. ChemMedChem, 2011, 6, 1119-1129.	1.6	11
196	Inhibition of ATP:l-methionine S-adenosyltrasferase of bakers' yeast by structural analogues of ATP. Biochimica Et Biophysica Acta - Biomembranes, 1973, 321, 467-474.	1.4	10
197	Nucleosides. CXIX. Substrate specificity and mechanism of action of cytidine deaminases of monkey plasma and mouse kidney. Chemico-Biological Interactions, 1981, 37, 41-54.	1.7	10
198	Synthesis of an N-aminopyrazinonium analog of cytidine. Journal of Medicinal Chemistry, 1983, 26, 283-286.	2.9	10

#	Article	IF	Citations
199	Differential Alteration of the Anti-HIV-1 Effect of Phosphorothioate Oligonucleotide S-dC28 by AZT, Interferon-Alpha, and Dextran Sulfate. AIDS Research and Human Retroviruses, 1991, 7, 943-951.	0.5	10
200	Preclinical pharmacology and pharmacokinetics of the anti-hepatitis virus agent 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil in mice and rats. Antimicrobial Agents and Chemotherapy, 1992, 36, 1472-1477.	1.4	10
201	A Comparison of Signaling Activities Induced by Taxol and Desoxyepothilone B. Journal of Chemotherapy, 2004, 16, 563-576.	0.7	10
202	Combined antiviral effects of paired nucleosides against guinea pig cytomegalovirus replication in vitro. Antiviral Research, 1990, 14, 249-265.	1.9	9
203	Synthetic and Antiviral Studies of Certain Acyclic 3′-Azido-3′-Deoxythymidine (AZT) Analogues. Nucleosides & Nucleotides, 1991, 10, 1407-1416.	0.5	9
204	DNA Interaction and Topoisomerase II Inhibition by the Antitumor Agent 3′-(9-Acridinylamino)-5′-hydroxymethylaniline and Derivatives. Bioorganic Chemistry, 1996, 24, 229-241.	2.0	9
205	<i>In vitro</i> Anti-HIV-1 Activity of <i>sn</i> -2-Substituted 1-O-Octadecyl- <i>sn</i> -Glycero-3-Phosphonoformate Analogues and Synergy with Zidovudine. Antiviral Chemistry and Chemotherapy, 2000, 11, 213-219.	0.3	9
206	Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer. Endocrine-Related Cancer, 2018, 25, 853-864.	1.6	9
207	In Vitro Anti-HIV-1 Synergy between Non-Nucleoside Reverse Transcriptase Inhibitors Nevirapine and Efavirenz. Antiviral Therapy, 2001, 6, 143-144.	0.6	9
208	Derivatives of 1-(2-Deoxy-2-fluoro- \hat{l}^2 -D-arabinofuranosyl)-5-phenyluracil and 5-Benzyluracil. Synthesis and Biological Properties. Nucleosides & Nucleotides, 1994, 13, 77-94.	0.5	8
209	Computerized quantification of drugs synergism in animal studies or in clinical trials using only ten data points. Synergy, 2019, 9, 100049.	1.1	8
210	Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. Endocrine-Related Cancer, 2019, 26, 727-738.	1.6	8
211	Effects of roniciclib in preclinical models of anaplastic thyroid cancer. Oncotarget, 2017, 8, 67990-68000.	0.8	8
212	Favorable Interactions between Enfuvirtide and $1\cdot\hat{l}^2$ -d-2,6-Diaminopurine Dioxolane In Vitro. Antimicrobial Agents and Chemotherapy, 2003, 47, 3644-3646.	1.4	7
213	Synthesis of New Camptothecin Analogues with the E-Lactone Ring Replaced by $\hat{l}\pm,\hat{l}^2$ -Cyclohexenone. European Journal of Organic Chemistry, 2006, 2006, 4490-4499.	1.2	7
214	In Vitro Inhibition of HIV-1 by Met-Sdf- $\hat{1}^2$ Alone or in Combination with Antiretroviral Drugs. Antiviral Therapy, 2000, 5, 199-204.	0.6	7
215	Synthesis of 4â€[(1,3â€diaminopyrrolo[3′,4′:4,5]pyrido[2,3â€ <i>d</i>) a€pyrimidinâ€8â€yl)benzoyl]â€Lâ€potential antifolate. Journal of Heterocyclic Chemistry, 1993, 30, 1437-1443.	glutamic a	acid as a
216	Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors. Annals of Oncology, 1999, 10, 601-603.	0.6	6

#	Article	IF	CITATIONS
217	BO-0742, a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors. Cancer Letters, 2009, 276, 204-211.	3.2	6
218	Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activityâ€"Letter. Cancer Research, 2011, 71, 2793-2793.	0.4	6
219	THE INHIBITION OF ESTERASES BY PALUDRINE. British Journal of Pharmacology and Chemotherapy, 1947, 2, 116-120.	1.5	5
220	The proliferative response of low-density human cell cultures to tumor promoters and its relevance to carcinogenic mechanismsin vitro. International Journal of Cancer, 1984, 34, 781-788.	2.3	5
221	Combined effects of interferon and steroid hormones on $2\hat{a}\in^2 5\hat{a}\in^2$ -oligoadenylate synthetase activity in chronic lymphocytic leukemia cells. Leukemia Research, 1989, 13, 437-443.	0.4	5
222	Carboxypeptidase G2 enhances trimetrexate cytotoxicity in CCRF-cem cell lines sensitive and resistant to methotrexate. Advances in Enzyme Regulation, 1989, 28, 323-333.	2.9	5
223	Enhanced Hydrolytic Stability and Water Solubility of an Aromatic Nitrogen Mustard by Conjugation with Molecular Umbrellas. Bioconjugate Chemistry, 2003, 14, 667-671.	1.8	5
224	Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells. Journal of Cancer Research and Clinical Oncology, 2005, 131, 609-616.	1.2	5
225	The Synthesis of Some Aryl Nitrogen Mustard Derivatives of Estrogens. Journal of Medicinal Chemistry, 1967, 10, 255-257.	2.9	4
226	Chemotherapy: Synergism and Antagonism. , 2002, , 473-484.		4
227	Efficacy of adavosertib therapy against anaplastic thyroid cancer. Endocrine-Related Cancer, 2021, 28, 311-324.	1.6	4
228	Therapeutic inhibition of poloâ€like kinases in anaplastic thyroid cancer. Cancer Science, 2021, 112, 803-814.	1.7	4
229	Antagonistic interactions of hexamethylene bisacetamide in combination with $1\cdot \hat{l}^2$ -d-arabinofuranosylcytosine, adriamycin and harringtonine on the growth and differentiation of HL-60 cells in vitro. Leukemia Research, 1988, 12, 853-859.	0.4	3
230	Cell differentiation effects of 2′-fluoro-1-β-d-arabinofuranosyl pyrimidines in HL-60 cells. Leukemia Research, 1987, 11, 1031-1039.	0.4	2
231	The enhancement of the activity of 10-propargyl-5,8-dideazafolate and 5,10-dideazatetrahydrofolate by inhibitors of dihydrofolate reductase. Advances in Enzyme Regulation, 1989, 28, 13-21.	2.9	2
232	2-Chloro-2′-deoxyadenosine synergistically enhances azidothymidine cytotoxicity in azidothymidine resistant T-lymphoid cells. Biochemical and Biophysical Research Communications, 2004, 316, 518-522.	1.0	2
233	Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer. Cancers, 2021, 13, 3487.	1.7	2
234	OCCURRENCE OF DEAMINATED MONOPHOSPHATE NUCLEOTIDE IN EXTRACELLULAR SITES AFTER GIVING ARABINOFURANOSYLCYTOSINE OR DEOXYCYTIDINE TO MICE. Annals of the New York Academy of Sciences, 1975, 255, 287-291.	1.8	1

#	Article	IF	CITATIONS
235	Overview: DNA Topoisomerase Targeted Anticancer Agents: New Trends and Developments. Current Opinion in Therapeutic Patents, 1992, 2, 1121-1139.	0.2	1
236	Synergistic growth inhibitory effects of interferon- \hat{l}_{\pm} and lovastatin on bcr-abl positive leukemic cells. International Journal of Oncology, 2003, 23, 151.	1.4	1
237	Rebuttal to the Response of Lee and Kong. Cancer Research, 2011, 71, 2796-2797.	0.4	1
238	A rigorous approach to the diagnosis of synergy among combination the rapies of immunosuppressive agents. , 2001, , 183-199.		1
239	Abstract 5526: Mass-action law algorithm-based computer simulation for efficient and econo-green cancer drug discovery and development, 2013, , .		1
240	Design of Antineoplastic Agents Based on the "2-Phenylnaphthalene-Type―Structural Pattern — Synthesis and Biological Activity Studies of 11H-Indolo[3.2-c]quinoline Derivatives ChemInform, 2003, 34, no.	0.1	0
241	Cover Picture: On the Remarkable Antitumor Properties of Fludelone: How We Got There (Angew.) Tj ETQq1 1 0.	784314 r _j 7.2	gBT ₀ /Overloc
242	Remarkable Antitumor Properties of Fludelone: How We Got There. ChemInform, 2005, 36, no.	0.1	0
243	Oncolytic herpes simplex virus shows synergistic effects with rapamycin against triple-negative breast cancer. Journal of the American College of Surgeons, 2013, 217, S139.	0.2	0
244	Abstract 3527: Therapeutic cure against five human xenograft tumors and strongly suppressed drug-resistant and refractory xenograft tumors in nude mice by the third generation epothilone: Iso-oxazole fludelone., 2011,,.		0
245	Abstract 2534: Novel and stable water-soluble N-mustards with potent therapeutic efficacy against human tumor xenografts in nude mice. , $2011, , .$		0
246	Abstract 3521: Alleviation of cancer chemotherapeutic agent-induced toxicity by the synthetic panaxytriol analogues of Panax Ginseng. , 2011 , , .		0
247	Abstract 1765: Potent antitumor BO-1922, derivative of indolizino [6,7-b] indole, against human colon, lung, and pancreatic cancers in xenograft model., 2012,,.		0
248	Comparison of massâ€action law algorithmâ€based pharmacodynamics with the conventional pharmacokinetic studies. FASEB Journal, 2013, 27, 516.13.	0.2	0
249	Comparison of massâ€action law algorithmâ€based pharmacodynamics with the conventional pharmacokinetic studies. FASEB Journal, 2013, 27, 665.2.	0.2	0
250	Computerized simulation and integration of biosystems based on the massâ€action law algorithms. FASEB Journal, 2013, 27, 572.1.	0.2	0
251	Abstract 4554A: Simple, efficient, and quantitative approach for determination of synergism, additive effect, and antagonism of drugsin vivousing combination index method: a proposition for clinical protocol design and regulatory synergy claims. , 2017, , .		0
252	Abstract 4554: Unified theoretical algorithms for graphics dynamic multiple transformations of dose-effect relationships with computer simulation. , 2017, , .		0